Why Sun Pharma’s massive Organon buyout is winning over investors where Lupin, Biocon failed

Managing the deal

The impact was also seen in today’s share performance, with Sun Pharmaceuticals’ shares closing up 6.83%. ₹1,731 on the National Stock Exchange. The stock was also the biggest gainer in the Nifty 50 index.

The stock fell 3.5% on Friday, mostly due to industry estimates for the deal to be worth more than $11.75 billion.